Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 20/20 | 1.00 |
| ▸ | TNF | P01375 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22655002 | 0.82 | IL1B (1.00) | IL1BTNF | |
| SCHEMBL22655194 | 0.77 | IL1B (1.00) | IL1BTNF | |
| SCHEMBL22695045 | 0.77 | IL1B (0.61) | IL1BTNF | |
| SCHEMBL22655124 | 0.76 | IL1B (1.00) | IL1BTNF | |
| SCHEMBL22695042 | 0.73 | IL1B (0.57) | IL1BTNF | |
| SCHEMBL22655138 | 0.73 | IL1B (0.57) | IL1BTNF | |
| SCHEMBL22689434 | 0.73 | IL1B (1.00) | IL1BTNF | |
| SCHEMBL22655092 | 0.73 | IL1B (1.00) | IL1BTNF | |
| SCHEMBL22689433 | 0.73 | IL1B (1.00) | IL1BTNF | |
| SCHEMBL31329508 | 0.73 | IL1B (1.00) | IL1BTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119732956-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-113784957-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| EP-3969441-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | claimed |
| CN-113784957-A | NLRP3 inflammasome inhibitor | 诺华股份有限公司 | 2021-12-10 | — | — | CN | claimed |
| WO-2020234715-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | claimed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| CN-119732956-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-113784957-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| EP-3969441-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| CN-113784957-A | NLRP3 inflammasome inhibitor | 诺华股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020234715-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885 |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885 |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885 |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885 |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885 |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | IL1B 11/4885TNF 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.